Available Clinical Trials

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724). E-mail: askrpci@roswellpark.org
 

(COG ADVL1522) A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; IND# 126953, NSC# 783609) in Children with Relapse or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST)...
Principal Investigator: Beaupin, Lynda K
(SWOG 1404) A Phase III Randomized Trial Comparing Physican/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma
Principal Investigator: Ernstoff, Marc S
(EAY 131-X MATCH): Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations
Principal Investigator: Levine, Ellis G
(EAY 131-V MATCH): Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
Principal Investigator: Levine, Ellis G
(EAY 131-U MATCH): VS-6063 (defactinib) in Patients with Tumors with NF2 Loss
Principal Investigator: Levine, Ellis G
A Randomized, Open-Label, Active-Controlled, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343) or Vinorelbine in Patients with Advanced or Metastatic Malignant Pleural Mesothelioma Overexpressing Mesothelin and Progressing on First Line...
Principal Investigator: Dy, Grace K
(EAY 131-T MATCH): GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
Principal Investigator: Levine, Ellis G
EAY 131-S2 MATCH): Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations
Principal Investigator: Levine, Ellis G
A Phase III Randomized Open- Label Study of Single Agent Pembrolizumab Vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That...
Principal Investigator: Boland, Patrick M
(EAY 131-S1 MATCH): Phase II Study of Trametinib in Patients with Tumors with NF1 mutations
Principal Investigator: Levine, Ellis G
(EAY 131-P MATCH): Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients with Tumors with PTEN Loss by IHC
Principal Investigator: Levine, Ellis G
(EAY 131-N MATCH): Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients with Tumors with PTEN Mutation or Deletion, with PTEN Expression on IHC
Principal Investigator: Levine, Ellis G
(EAY 131-I MATCH): GDC-0032 (taselisib) in Patients with Tumors (other than breast cancer) with PIK3CA Mutation but without KRAS Mutation or PTEN Loss
Principal Investigator: Levine, Ellis G
(EAY 131-B MATCH): Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations
Principal Investigator: Levine, Ellis G
(EAY 131-E MATCH): AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
Principal Investigator: Levine, Ellis G
(EAY 131-R MATCH): Phase II Study of Trametinib in Patients with BRAF Fusions, or With Non-V600E, Non-V600K BRAF Mutations
Principal Investigator: Levine, Ellis G
(EAY 131-H MATCH): Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer)
Principal Investigator: Levine, Ellis G
(EAY 131-G MATCH): Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer)
Principal Investigator: Levine, Ellis G
(EAY 131-F MATCH): Crizotinib in Patients with Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Translocations
Principal Investigator: Levine, Ellis G
(EAY 131-A MATCH): Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
Principal Investigator: Levine, Ellis G
(EAY 131 Master Protocol) Molecular Analysis for Therapy Choice (MATCH)
Principal Investigator: Levine, Ellis G
Phase 0 Trial of Presurgical Cholesterol-lowering on Prostate Cancer Cell Growth
Principal Investigator: Mohler, James L
(COG AAML1522/CC-5013-AML-002) A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid®) in Pediatric Subjects from 1 to = 18 Years of Age with Relapsed or Refractory Acute...
Principal Investigator: Twist, Clare J
A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Principal Investigator: Chen, Hongbin
(A071101) A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex -96 (HSPPC-96) (NSC #725085, Alliance IND #15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable...
Principal Investigator: Abad, Ajay P
(A071102) A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter HyperMethylation
Principal Investigator: Abad, Ajay P
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung...
Principal Investigator: Chen, Hongbin
A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Principal Investigator: Lee, Kelvin
A Phase 3, Multicenter, Open-Label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
Principal Investigator: Wang, Eunice S
(EA1131) A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Principal Investigator: Levine, Ellis G
Single-Arm, Non-Inferiority Study of Omission of Intraoperative Intact Parathyroid Hormone (PTH) during Minimally Invasive Parathyroidectomy for Primary Hyperparathyroidism
Principal Investigator: Kukar, Moshim
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
Principal Investigator: Thompson, J E
(COG APEC14B1) The Project: Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Principal Investigator: Bambach, Barbara J
The ROCKET Study: A Phase 2, Single-arm, Multicenter Trial to Determine the Efficacy and Safety of JCAR015 in Adult Subjects with Relapse or Refractory B-Cell Acute Lymphoblastic Leukemia (ALL)
Principal Investigator: Wang, Eunice S
A Phase Ib/II Study of Cetuximab and Pembrolizumab in Metastatic Colorectal Cancer
Principal Investigator: Boland, Patrick M
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Principal Investigator: Levine, Ellis G
A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Treated Locally Advanced Unresectable or Metastatic (Stage IV) Mismatched Repair Deficient or Microsatellite Instability-High Colorectal Carcinoma (KEYNOTE-164)
Principal Investigator: Boland, Patrick M
(ALXN1007-GIGVHD-201) A Phase 2A Study of ALXN1007 in Subjects with Newly Diagnosed Acute Graft-Versus-Host Disease Involving the Lower Gastrointestial Tract
Principal Investigator: Chen, George L
(S1314) A Randomized Phase II Study Of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Principal Investigator: Levine, Ellis G
A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Activity of Oraxol in Subjects with Advanced Malignancies
Principal Investigator: Boland, Patrick M
Nicotine Delivery From Novel Non-Tobacco Electronic Systems (ENDS)
Principal Investigator: Mahoney, Martin C
(ACCL1333/CV185-155) A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly...
Principal Investigator: Bambach, Barbara J
(S1318) A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6 Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and...
Principal Investigator: Wang, Eunice S
(2215-CL-0301) A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
Principal Investigator: Wang, Eunice S
Effect of CTAP101 Capsules on Serum Calcium, Plasma Intact Parathyroid Hormone and Vitamin D Metabolites in Patients with Advanced Breast and Prostate Carcinomas with Metastases to Bone and Receiving Ongoing Therapy with Denosumab or Zoledronic Acid
Principal Investigator: O'Connor, Tracey L
A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer and Melanoma
Principal Investigator: Opyrchal, Mateusz
(RU0214071) Regorafenib Dose Optimization Study (ReDOS); A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients with Refractory Metastatic Colorectal Cancer (mCRC)
Principal Investigator: Boland, Patrick M
(MM-141-07-0202) A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of MM-141 Plus Nab-Paclitaxel and Gemcitabine Versus Nab-Paclitaxel and Gemcitabine in Front-Line Metastatic Pancreatic Cancer (CARRIE)
Principal Investigator: Boland, Patrick M
(COG AALL1331) Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC# 765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Principal Investigator: Bambach, Barbara J
Gemtuzumab ozogamicin (MYLOTARG) expanded access protocol for treatment of patients in the United States with relapsed/ refractory acute myelogenous leukemia who may benefit from treatment and have no access to other comparable/alternative therapy
Principal Investigator: Wang, Eunice S
A Phase II, Multicenter, Four-Cohort Study of Oral cMET Inhibitor INC280 in Adult Patients with EGFR Wild-Type (wt), Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Received One or Two Prior Lines of Systemic Therapy for Advanced/Metastatic Disease
Principal Investigator: Chen, Hongbin
(COG AEWS1221) Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Principal Investigator: Beaupin, Lynda K
(COG ANBL1232) Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
Principal Investigator: Higman, Meghan
Nab-Paclitaxel (ABRAXANE®) Plus Gemcitabine in Subjects with Locally Advanced Pancreatic Cancer (LAPC): An International, Open-Label, Multi-Center, Phase 2 Study (LAPACT)
Principal Investigator: Iyer, Renuka V
(STML-401-0214) A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients with Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
Principal Investigator: Wang, Eunice S
SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Principal Investigator: Wang, Eunice S
A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
Principal Investigator: Fenstermaker, Robert A
(PCYC-1131-CA) A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects with Acute Myeloid Leukemia
Principal Investigator: Wang, Eunice S
(S1400) A Biomarker-Driven Master Protocol for Previously treated Squamous Cell Lung Cancer (Lung-Map)
Principal Investigator: Chen, Hongbin
(ARO-006) A Safety and Tolerability Trial of Crenolanib and Chemotherapy with Cytarabine and Anthracyclines in Patients with Newly Diagnosed Acute Myeloid Leukemia with FLT3 Activating Mutations
Principal Investigator: Wang, Eunice S
Multicenter Phase II Study of Nintedanib for Patients with Advanced Carcinoid Tumors
Principal Investigator: Iyer, Renuka V
A Phase I/II Study of Nintedanib and Capecitabine in Refractory Metastatic Colorectal Cancer
Principal Investigator: Boland, Patrick M
Analysis of Analgesia Regimens during Concurrent Chemoradiation for Head and Neck Cancer: A Pilot Study
Principal Investigator: Singh, Anurag K
(C31001) A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment...
Principal Investigator: Opyrchal, Mateusz
(E4512 )A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Principal Investigator: Chen, Hongbin
(A081105) Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator: Dy, Grace K
(A151216) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Principal Investigator: Dy, Grace K
(PIN-PHO1201) Multicenter, Open-Label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Principal Investigator: Bain, Andrew J
(COG ALTE11C1) Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma
Principal Investigator: Rokitka, Denise A
(NRG/COG ARST1321) Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
Principal Investigator: Salerno, Kilian E
A Randomized, Open Label Phase 2 Study of the Selective Inhibitor of Nuelear Export (SINE), Selinexor (KPT-330) Versus Specified Physician's Choice in Patients > or Equal to 60 Years Old with Relapsed/Refractory Acute Myeloid Leukemia (AML) Who are...
Principal Investigator: Wang, Eunice S
(BMT CTN 1102) A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic...
Principal Investigator: McCarthy, Philip L
Phase I Study of Oral PQR309 in Patients with Advanced Solid Tumors
Principal Investigator: Opyrchal, Mateusz
(COG AALL1231) A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphobalstic Lymphoma (T-LLy)
Principal Investigator: Bambach, Barbara J
(E2112) A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
Principal Investigator: Levine, Ellis G
Two Versus Four Times-Weekly ALTENS for Treatment of Radiation-Induced Xerostomia: A Pilot Study
Principal Investigator: Singh, Anurag K
(E1910) A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Principal Investigator: Wang, Eunice S
(AC220-007) A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed After First-Line Treatment With or Without...
Principal Investigator: Wang, Eunice S
A Dose-Regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects with Advanced Malignancies
Principal Investigator: Boland, Patrick M
(BAY ONC-3012-036) A Phase II Single-Arm Study of Regorafenib Maintenance Therapy in Patients with T3, T4 or Node-Positive Rectal Cancer Patients who completed Curative-Intent Treatment
Principal Investigator: Boland, Patrick M
(CA-ALT-803-02-13) A Study of ALT-803 in Patients with Relapsed or Refractory Multiple Myeloma
Principal Investigator: Lee, Kelvin
(UPCC 14153) A Randomized Phase II Trial of Radical Pleurectomy and Post-Operative Chemotherapy With or Without Intraoperative Porfimer Sodium-Mediated Photodynamic Therapy for Patients with Epithelioid Malignant Pleural Mesothelioma
Principal Investigator: Yendamuri, Sai S
A Phase I Study of Ceritinib (LDK378), a Novel ALK Inhibitor, in Combination with Gemcitabine-Based Chemotherapy in Patients with Advanced Solid Tumors
Principal Investigator: Iyer, Renuka V
(E1412) Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
(BP-HM-001) A Phase 1-2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells after Partially Mismatched, Related T Cell-Depleted HSCT
Principal Investigator: Chen, George L
(BAY 1129980/16044) An Open-Label Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-C4.4a Antibody Drug Conjugate BAY 1129980 in Subjects With Advanced Solid...
Principal Investigator: Opyrchal, Mateusz
Neoadjuvant AGS-003 Immunotherapy in Patients with Localized Kidney Cancer <pT2
Principal Investigator: Schwaab, Thomas
(CX-839-003) A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamices of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 as a Single Agent and in Combonation with Standard Therapy in Patients with Relapsed Refractory Leukemia...
Principal Investigator: Wang, Eunice S
(BMT CTN 1204) Reduced-Intensity Conditioning for Children and Adults with Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (RICHI)
Principal Investigator: Bambach, Barbara J
A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given with Adjuvant Poly-ICLC in Combination with INCB024360 for Patients in Remission with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY...
Principal Investigator: Odunsi, Adekunle O
(A011202) A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 NI) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Principal Investigator: Levine, Ellis G
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Principal Investigator: Wang, Eunice S
(Alliance A011106) ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Principal Investigator: Levine, Ellis G
A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination with Tremelimumab in Subjects With Advanced Solid Tumors
Principal Investigator: Odunsi, Adekunle O
A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects with Metastatic Urothelial Cancer
Principal Investigator: George, Saby
Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults with CD20+ Mature B-Cell Lymphoma
Principal Investigator: Barth, Matthew J
(GOG 274) A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation alone: The OUTBACK trial
Principal Investigator: Frederick, Peter
Data Collection for Light Dosimetry and Treatment Planning Development for Photodynamic Therapy (PDT)
Principal Investigator: Arshad, Hassan
Phase I/II Study of Carfilzomib plus Rituximab plus Ifosfamide plus Carboplatin plus Etoposide (C-R-ICE) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
N1048 PROSPECT**) A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiaiton Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with...
Principal Investigator: Nurkin, Steven J
(SWOG S1216) A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
Principal Investigator: Levine, Ellis G
A Phase II Study of Single Agent Topoisomerase-I Inhibitor Polymer Conjugate, Etirinotecan Pegol (NKTR-102), in Patients with Relapsed Small Cell Lung Cancer
Principal Investigator: Chen, Hongbin
A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) with Temoporfin in Patients with Resectable Primary Non-Small Cell Lung Cancer (NSCLC) with Ipsilateral Thoracic Nodal (N1 or N2) or T3/T4 Disease
Principal Investigator: Nwogu, Chukwumere E
Multicenter Phase 1b/2 Study of Tivozanib in Patients with Advanced Inoperable Hepatocellular Carcinoma
Principal Investigator: Iyer, Renuka V
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of Pinatuzumab Vedotin (DCDT2980S) in Combination with Rituximab or Polatuzumab Vedotin (DCDS4501A) in Combination with Rituximab and a Non-Randomized Phase Ib/II...
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
Clinical Trial Methods for Assessing a Tobacco Product
Principal Investigator: Mahoney, Martin C
Alternative Approaches for Nausea Control
Principal Investigator: O'Connor, Tracey L
Pilot: Impact of High-Dose, Single Fraction Radiation on Immunogenicity of Sipuleucel-T in Metastatic Castration Recurrent Prostate Cancer Patients
Principal Investigator: Schwaab, Thomas
A Phase I Trial of a Recombinant Human hsp110-gp100 Chaperone Complex Vaccine for Advanced Stage IIIB/C or IV Melanoma
Principal Investigator: Kane, John M
Impact of Carbonyl Reductase 3 Genotype Status on Echocardiographic Measurements of Cardiomyopathy in Breast Cancer Patients Treated with Anthracyclines
Principal Investigator: O'Connor, Tracey L
A Pilot Study of Broccoli Sprout Extract in Patients with Breast Cancer
Principal Investigator: Young, Jessica S
(COG AAML1031) A Phase 3 Randomized Trial for Patients with de novo AML Using Bortezomib and Sorafenib (IND#114480; NSC#681239, NSC#724772) for Patients with High Allelic Ratio FLT3/ITD
Principal Investigator: Beaupin, Lynda K
A Pilot Study of the Flaxseed Effects on Hormones and Lignans: Role of Race, Genes, and Gut Microbiome
Principal Investigator: McCann, Susan E
Influence of Advertising Claim Presentation on Beliefs and Affective Associations Related to Tobacco Products
Principal Investigator: O'Connor, Richard J
A Phase I/ II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients
Principal Investigator: George, Saby
PNH Registry
Principal Investigator: Griffiths, Elizabeth A
A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up...
Principal Investigator: McCarthy, Philip L
(COG ANHL04B1) Rare and Cutaneous Non-Hodgkin Lymphoma Registry
Principal Investigator: Barth, Matthew J
A Pilot Study Evaluating NFAT, NFkB and, ERK 1/2 Nuclear Translocation as a Predictive Marker for Acute Graft-versus-Host Disease
Principal Investigator: Chen, George L
(COG ACCL0933) A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Principal Investigator: Bambach, Barbara J
(CIBMTR 10-CBA) A Multicenter Access and Distribution Protocol for Unlicensed Cryopreseved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
Principal Investigator: McCarthy, Philip L
(COG AAML08B1) Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)
Principal Investigator: Higman, Meghan
Ofatumumab (O) in Combination With Chemotherapy: Hyper-Fractionated Cyclophosphamide, Doxorubicin, Vincristine and Dexamethasone (O-HyperCVAD) Alternating With Ofatumumab High-Dose Cytarabine and Methotrexate (O-MA) for Patients With Newly Diagnosed...
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
Correlation of Deuterated Phenanthrene Metabolism with Bronchoepitheial Dysplasia and Metaplasia in Current and Former Smokers at High Risk for Lung Cancer
Principal Investigator: Dhillon, Samjot
Evaluation of Pre-Operative Nutritional Risk as a Predictor of Post-Operative Outcome in Patients Undergoing Robot-Assisted Radical Cystectomy
Principal Investigator: Guru, Khurshid
Examining Quality of Life Among Long-Term Survivors of Childhood Cancer
Principal Investigator: Rokitka, Denise A
Mediators of inflammation and injury in patients receiving cancer therapy or allogeneic hematopoietic stem cell transplantation
Principal Investigator: Segal, Brahm
A Correlative Study of Lung Cancer Treatment Response
Principal Investigator: Singh, Anurag K
(COG ACNS0831) Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years
Principal Investigator: Fitzpatrick, Lorna
(COG AALL0932) Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)
Principal Investigator: Bambach, Barbara J
(COG AALL08B1) Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Principal Investigator: Bambach, Barbara J
Phase I Study of LBH589, A Novel Oral Deacetylase Inhibitor in Patients with Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
(COG ALTE03N1) Key Adverse Events After Childhood Cancer
Principal Investigator: Rokitka, Denise A
Evaluation & Quality Assurance of the New York State Smokers' Quitline
Principal Investigator: Hyland, Andrew J
Novel Risk Factors and Potential Early Detection Markers for Ovarian Cancer
Principal Investigator: Moysich, Kirsten B
Collection of Blood from Healthy Donors and Patients with Non-Hodgkin's Lymphoma to Study the Immunological Activity of Peripheral Blood Mononuclear Cells (PBMC) and Human Serum
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation with Unrelated Donors (NMDP IRB 1996-005; IRB-1999-0021)
Principal Investigator: McCarthy, Philip L
Leukocyte Apheresis for Research
Principal Investigator: Odunsi, Adekunle O
Lung Bronchoscopy Research Samples & Database
Principal Investigator: Reid, Mary E
Evaluation of Smoker Reactions to Novel Tobacco Products
Principal Investigator: Bansal Travers, Maansi
Genetic Signature for Progression of Barrett's Esophagus to Esophageal Adenocarcinoma. A Pilot Study
Principal Investigator: Bain, Andrew J
Brody Belt
Principal Investigator: Guru, Khurshid
Assessment of Tumor Cell Viability and Various Biomarkers from De-Identified Bladder Washing Samples Obtained From Patients with Bladder Carcinoma
Principal Investigator: Guru, Khurshid
Easing the transition to Post-Treatment Status for Breast Cancer Patients
Principal Investigator: Hydeman, Jennifer A
(COG ALTE05N1) Umbrella Long-Term Follow-Up Protocol
Principal Investigator: Rokitka, Denise A
Molecular Mechanisms Involved in Cancer Predisposition
Principal Investigator: Voian, Nicoleta C
Intensity Modulated Radiation Therapy for Anal Cancer: Dosimetric Comparison, Acute Toxicity Profile, and Quality of Life Assessment
Principal Investigator: Mattson, David
(COG AHEP0731) Treatment of Children with All Stages of Hepatoblastoma
Principal Investigator: Rokitka, Denise A
Randomized Placebo-Controlled, Double-Blind Study Of Cholecalciferol Replacement in Patients on Expectant Management for Localized Prostate Cancer
Principal Investigator: Mohler, James L
(CALGB 140503) A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (< 2 cm) Peripheral Non-Small Cell Lung Cancer
Principal Investigator: Nwogu, Chukwumere E
(COG ACNS0332) Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Principal Investigator: Fitzpatrick, Lorna
Women's Health After Breast Cancer Study
Principal Investigator: Hong, Chi-Chen